ILMN
Illumina Inc.
Is ILMN Halal?
Genomics instruments are generally permissible, subject to clinical and data-use review.
What You Should Know
Illumina's March 29, 2026 filing shows debt/assets of 30.32%, liquidity/assets of 16.60%, receivables plus cash/assets of 27.85% and disclosed interest income/revenue of 1.01%. Sequencing, array-based analysis, consumables and services support research and health, while reproductive health, consumer genomics, agriculture, clinical, government and pharmaceutical applications require qualitative review.
⚠️ Concerns
- •Clinical, reproductive-health and human-genomics uses require scholarly, consent and privacy review
- •Consumer-genomics and genetic-data processing create material data-governance risks
- •Government, agriculture and pharmaceutical applications are not separately quantified
- •Financial ratios pass the examined asset-based screens, but business classification remains incomplete
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-29; calculated 2026-07-14.
1,989 / 6,559
1,089 / 6,559
1,827 / 6,559
11 / 1,091
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 30.32%, liquidity/assets is 16.60%, receivables plus cash/assets is 27.85% and interest income/revenue is 1.01%, below the examined limits; business classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 30.32%, liquidity/assets is 16.60% and receivables plus cash/assets is 27.85%, below the examined MSCI total-assets limits; activity classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
The examined ratios pass at debt/assets 30.32% and liquidity/assets 16.60%; activity classification remains incomplete and this is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored and business classification remains incomplete, so market-cap methods are not estimated from a current spot price.
Business-activity disclosure
Illumina provides sequencing- and array-based genomic-analysis systems, consumables and services for research, clinical and applied markets. Genomics and diagnostic instrumentation are generally permissible and can support health, while reproductive health, consumer genomics, agriculture, clinical research and data uses require continuing qualitative review.
Limitation: The filing does not allocate revenue into a universal prohibited-activity numerator for reproductive-health, consumer-genomics, agriculture, clinical, government or pharmaceutical customer applications.
Purification
Illumina discloses $11 million of interest income but does not prescribe a scholar-approved purification percentage; the disclosed ratio is evidence for the income screen, not a complete purification prescription.
Inputs, assumptions and primary sources
- Amounts are USD millions from Illumina's March 29, 2026 Form 10-Q and rounded to the nearest million.
- Term debt is $499 million current portion plus $1,490 million long-term term debt; operating leases are excluded.
- Cash and cash equivalents are $1,089 million. The $66 million of short-term investments are identified as marketable equity securities and are not added as interest-bearing securities.
- Accounts receivable, net are $738 million and first-quarter total revenue is $1,091 million; disclosed interest income is $11 million.
- Illumina's fiscal quarter ended March 29, 2026 rather than calendar quarter-end.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →